Evidence map›Paper›PMID 41679923›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Phase 2 Prospective Trial of Retreatment with [

John Nikitas, Adrien Holzgreve, Jesus Juarez, Koichiro Kimura, Stephanie Lira, Hamzah Alam, Maria Contreras, Lela Theus, Andrew T Nguyen, Zachary Ells and 8 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

John NikitasDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Adrien HolzgreveAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Jesus JuarezAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Koichiro KimuraAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Stephanie LiraAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Hamzah AlamAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Maria ContrerasAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Lela TheusAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Andrew T NguyenAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Zachary EllsAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Shaojun ZhuAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Tristan GroganDepartment of Medicine Statistics Core, UCLA, Los Angeles, California.
David A ElashoffDepartment of Medicine Statistics Core, UCLA, Los Angeles, California.
Lena M UnterrainerAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Magnus DahlbomAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Johannes CzerninAhmanson Translational Theranostics Division, UCLA, Los Angeles, California.
Jeremie CalaisAhmanson Translational Theranostics Division, UCLA, Los Angeles, California; jcalais@mednet.ucla.edu.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

[

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedHumansMaleNeoplasm MetastasisProspective StudiesProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsRetreatmentTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals[177Lu]Lu-PSMA-617mCRPCmetastatic castration-resistant prostate cancerprostate-specific membrane antigenPSMAradiopharmaceutical therapy

Identifiers

PMID41679923
PMCPMC13138109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.